ADVERTISEMENT

Brazil suspends Bharat Biotech's Covaxin clinical trials

July 24, 2021 10:32 am | Updated 10:32 am IST - Hyderabad

The move comes after termination of the Hyderabad-based firm’s agreement with its partner.

Brazil has suspended the clinical studies of Bharat Biotech's COVID-19 vaccine , Covaxin following termination of the company's agreement with its partner there, the South American Country's health regulator said.

Bharat Biotech on Friday, July 23, 2021 announced cancellation of the MoU it signed with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for its COVID-19 vaccine Covaxin for the Brazilian market.

The termination of the pact comes after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.

ADVERTISEMENT

"In the Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil The suspension was carried out as a result of a statement from the Indian company Bharat Biotech Limited International, sent to Anvisa on Friday (23/7), Anvisa, the Brazilian health regulator, said on Friday.

Precisa Medicamentos was Bharat Biotechs partner in Brazil, providing assistance, guidance and support with regulatory submissions, licensure, distribution, insurance and conduct of phase III clinical trials, among others.

Following the graft allegations, the

ADVERTISEMENT

Brazilian government has suspended Covaxin's order temporarily.

ADVERTISEMENT

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT